Invesco Ltd. Aeglea Bio Therapeutics, Inc. Transaction History

Invesco Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.5 - $2.66 $6,175 - $32,851	-12,350 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.87 - $4.77 $258 - $658	138 Added 1.13%	12,350 $29,000
Q4 2021 Feb 14, 2022	SELL	$3.5 - $8.42 $8,799 - $21,167	-2,514 Reduced 17.07%	12,212 $58,000
Q3 2021 Nov 15, 2021	BUY	$6.03 - $7.95 $10,136 - $13,363	1,681 Added 12.89%	14,726 $117,000
Q2 2021 Aug 17, 2021	BUY	$6.32 - $8.38 $82,444 - $109,317	13,045 New	13,045 $90,000
Q3 2020 Nov 16, 2020	SELL	$6.51 - $9.33 $407,968 - $584,692	-62,668 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$4.01 - $11.04 $251,298 - $691,854	62,668 New	62,668 $580,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.